Menu Search
Equities

Raily Aesthetic Medicine International Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2135:HKG.HZ

Raily Aesthetic Medicine International Holdings Ltd

Actions
  • Price (HKD)0.150
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change+40.19%
  • Beta0.6765
Data delayed at least 15 minutes, as of Feb 13 2026 02:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Raily Aesthetic Medicine International Holdings Ltd is an investment holding company primarily engaged in the provision of aesthetic medical services. The Company's main business is to provide customers with aesthetic medical services, including aesthetic surgery services, minimally-invasive aesthetic services and aesthetic dermatology services. The Company operates its businesses through three business segments. The Aesthetic Medical Services segment comprises principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others. The Consulting Services segment comprises principally management consulting services. The Aesthetic Medical Equipment Products segment comprises principally sales of collagen injection products, surgical implants and aesthetic medical skincare products. The Company mainly conducts its businesses within domestic market.

  • Revenue in HKD (TTM)188.32m
  • Net income in HKD-73.72m
  • Incorporated2018
  • Employees289.00
  • Location
    Raily Aesthetic Medicine International Holdings LtdNo. 290 North Zhongshan RoadXiacheng District, 3-5/F, Minhang TowerHANGZHOU ChinaCHN
  • Websitehttp://www.raily.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.